STAT+: Roche to buy PathAI for $750 million

STAT PlusHealth tech Roche to buy PathAI for $750 million The move comes after Roche and PathAI began a partnership in 2021 Manage alerts for this article Email this article Share this article By Jonathan Saltzman — Boston GlobeMay 8, 2026 Roche has signed a deal to pay $750 million upfront for Boston-based PathAI, an acquisition by the Swiss pharmaceutical giant to speed up its use of artificial intelligence to help pathologists diagnose disease. The agreement, which is expected to close in the second half of the year, could generate an additional $300 million for PathAI if it leads to the achievement of certain milestones.Advertisement “Joining forces with Roche marks a new era for PathAI, enabling us to realize our mission of improving patient outcomes through AI-powered pathology at unprecedented scale and speed,” said Andy Beck, chief executive and cofounder of PathAI, in a statement. “Roche’s global infrastructure and expertise will bring our digital diagnostics technology to patients worldwide.” STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In Artificial intelligence, health tech, Pharmaceuticals, STAT+ Submit a correction requestReprints Jonathan Saltzman — Boston Globe Newsletter Tech is transforming health care and life sciences. Our original reporting is here to keep you ahead of the curve. Recommended Breaking News May 8, 2026 Trump reportedly plans to fire FDA Commissioner Makary Pharmalot May 8, 2026 STAT Plus: Capricor Therapeutics accuses Nippon Shinyaku of slow-walking plans on Duchenne drug Advertisement First Opinion May 8, 2026 I’m fighting misinformation online. False hantavirus claims follow a now-familiar playbook Politics May 8, 2026 Former FDA leaders, pharma speak out on mifepristone Pharmalot May 8, 2026 STAT Plus: Up and down the ladder: The latest comings and goings Subscriber Picks